Study of AZD9829 in CD123+ Hematological Malignancies
Status:
Recruiting
Trial end date:
2026-08-04
Target enrollment:
Participant gender:
Summary
This is a modular, multicentre, open-label, Phase I/II, dose-setting study. AZD9829 will be
administered intravenously as monotherapy or in combination in participants with CD123
positive hematological malignancies.